Symbols / INSM $144.48 +2.48% Insmed Incorporated
INSM Chart
About
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Fundamentals
Scroll to Statements| Market Cap | 31.19B | Enterprise Value | 30.46B | Income | -1.28B | Sales | 606.42M | Book/sh | 3.45 | Cash/sh | 6.63 |
| Dividend Yield | — | Payout | 0.00% | Employees | 1664 | IPO | — | P/E | — | Forward P/E | 192.87 |
| PEG | 1.09 | P/S | 51.43 | P/B | 41.89 | P/C | — | EV/EBITDA | -31.07 | EV/Sales | 50.23 |
| Quick Ratio | 3.35 | Current Ratio | 3.83 | Debt/Eq | 101.43 | LT Debt/Eq | — | EPS (ttm) | -6.42 | EPS next Y | 0.75 |
| EPS Growth | — | Revenue Growth | 152.60% | Earnings | 2026-05-07 | ROA | -28.99% | ROE | -249.28% | ROIC | — |
| Gross Margin | 79.73% | Oper. Margin | -94.64% | Profit Margin | -210.54% | Shs Outstand | 215.85M | Shs Float | 193.23M | Short Float | 7.19% |
| Short Ratio | 5.69 | Short Interest | — | 52W High | 212.75 | 52W Low | 63.81 | Beta | 1.10 | Avg Volume | 2.32M |
| Volume | 1.70M | Target Price | $212.50 | Recom | Strong_buy | Prev Close | $140.98 | Price | $144.48 | Change | 2.48% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-17 | reit | Roth Capital | Buy → Buy | $212 |
| 2026-04-14 | main | RBC Capital | Outperform → Outperform | $216 |
| 2026-04-01 | main | Barclays | Overweight → Overweight | $237 |
| 2026-03-30 | up | Morgan Stanley | Equal-Weight → Overweight | $212 |
| 2026-03-26 | main | HC Wainwright & Co. | Buy → Buy | $245 |
| 2026-03-25 | main | Mizuho | Outperform → Outperform | $206 |
| 2026-03-24 | main | Leerink Partners | Outperform → Outperform | $215 |
| 2026-03-24 | main | Stifel | Buy → Buy | $208 |
| 2026-03-24 | main | Wells Fargo | Overweight → Overweight | $177 |
| 2026-03-24 | main | B of A Securities | Buy → Buy | $213 |
| 2026-03-23 | main | Wells Fargo | Overweight → Overweight | $175 |
| 2026-02-24 | main | Mizuho | Outperform → Outperform | $204 |
| 2026-02-23 | reit | HC Wainwright & Co. | Buy → Buy | $230 |
| 2026-02-20 | main | Wells Fargo | Overweight → Overweight | $208 |
| 2026-01-30 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $162 |
| 2026-01-28 | init | Barclays | — → Overweight | $231 |
| 2026-01-23 | init | Roth Capital | — → Buy | $212 |
| 2026-01-21 | main | RBC Capital | Outperform → Outperform | $200 |
| 2026-01-06 | main | UBS | Buy → Buy | $215 |
| 2025-12-18 | main | TD Cowen | Buy → Buy | $241 |
- Is Insmed Incorporated (INSM) stock mispriced | Q4 2025: Earnings Underperform - Catalyst Event - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 12
- Insmed Incorporated (INSM) Stock Analysis: Potential 47% Upside With Strong Buy Ratings - DirectorsTalk Interviews Mon, 20 Apr 2026 09
- Insmed (INSM): Top QQQ stock to buy now - MSN ue, 21 Apr 2026 13
- Insmed Provides Clinical Update on Phase 2b CEDAR Study - PR Newswire ue, 07 Apr 2026 07
- Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance Mon, 30 Mar 2026 07
- A Look At Insmed (INSM) Valuation After Brensocatib Setback In Hidradenitis Suppurativa - simplywall.st Sun, 19 Apr 2026 11
- INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan Fri, 17 Apr 2026 20
- Avoiding Lag: Real-Time Signals in (INSM) Movement - Stock Traders Daily ue, 21 Apr 2026 21
- Insmed chair and CEO William Lewis sells $1.54m in stock - Investing.com Fri, 17 Apr 2026 21
- INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset - Zacks Investment Research hu, 18 Dec 2025 08
- INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced - Yahoo Finance Mon, 12 Jan 2026 08
- William Lewis lists INSM share sales (NASDAQ: INSM) in Form 144 filing - Stock Titan hu, 16 Apr 2026 20
- Mizuho lowers Insmed stock price target on failed trial data - Investing.com Wed, 08 Apr 2026 07
- INSM Stock Up 78% in 6 Months: Here's What You Need to Know - Yahoo Finance Fri, 02 Jan 2026 08
- Here’s What Lifted Insmed Incorporated (INSM) in Q3 - Yahoo Finance Mon, 17 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
606.42
+66.73%
|
363.71
+19.17%
|
305.21
+24.39%
|
245.36
|
| Operating Revenue |
|
606.42
+66.73%
|
363.71
+19.17%
|
305.21
+24.39%
|
245.36
|
| Cost Of Revenue |
|
122.94
+43.38%
|
85.74
+30.76%
|
65.57
+18.95%
|
55.13
|
| Reconciled Cost Of Revenue |
|
112.49
+41.00%
|
79.78
+32.87%
|
60.05
+20.46%
|
49.85
|
| Gross Profit |
|
483.49
+73.94%
|
277.96
+16.00%
|
239.63
+25.97%
|
190.23
|
| Operating Expense |
|
1,478.26
+38.86%
|
1,064.54
+15.64%
|
920.56
+37.74%
|
668.36
|
| Research And Development |
|
771.09
+28.87%
|
598.37
+4.79%
|
571.01
+43.64%
|
397.52
|
| Selling General And Administration |
|
701.17
+52.06%
|
461.12
+33.85%
|
344.50
+29.62%
|
265.78
|
| General And Administrative Expense |
|
701.17
+52.06%
|
461.12
+33.85%
|
344.50
+29.62%
|
265.78
|
| Salaries And Wages |
|
331.16
+52.15%
|
217.66
+38.79%
|
156.82
+26.45%
|
124.02
|
| Other Gand A |
|
370.00
+51.98%
|
243.46
+29.72%
|
187.68
+32.38%
|
141.77
|
| Total Expenses |
|
1,601.20
+39.20%
|
1,150.28
+16.64%
|
986.14
+36.30%
|
723.48
|
| Operating Income |
|
-994.78
-26.47%
|
-786.57
-15.51%
|
-680.93
-42.42%
|
-478.12
|
| Total Operating Income As Reported |
|
-1,246.77
-41.96%
|
-878.25
-23.76%
|
-709.63
-55.17%
|
-457.32
|
| EBITDA |
|
-1,177.72
-43.84%
|
-818.79
-24.03%
|
-660.18
-47.57%
|
-447.37
|
| Normalized EBITDA |
|
-986.38
-26.43%
|
-780.18
-15.77%
|
-673.93
-41.07%
|
-477.72
|
| Reconciled Depreciation |
|
16.45
+49.37%
|
11.01
+4.10%
|
10.58
+2.40%
|
10.33
|
| EBIT |
|
-1,194.17
-43.91%
|
-829.81
-23.71%
|
-670.76
-46.55%
|
-457.70
|
| Total Unusual Items |
|
-191.34
-395.55%
|
-38.61
-380.71%
|
13.76
-54.69%
|
30.36
|
| Total Unusual Items Excluding Goodwill |
|
-191.34
-395.55%
|
-38.61
-380.71%
|
13.76
-54.69%
|
30.36
|
| Special Income Charges |
|
-251.99
-174.86%
|
-91.68
-219.48%
|
-28.70
-237.95%
|
20.80
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
251.99
+174.86%
|
91.68
+219.48%
|
28.70
+237.95%
|
-20.80
|
| Net Income |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Pretax Income |
|
-1,271.75
-39.74%
|
-910.07
-21.83%
|
-747.01
-55.58%
|
-480.15
|
| Net Non Operating Interest Income Expense |
|
-83.80
+1.32%
|
-84.91
-3.94%
|
-81.69
-208.91%
|
-26.45
|
| Interest Expense Non Operating |
|
77.58
-3.34%
|
80.26
+5.25%
|
76.26
+239.59%
|
22.45
|
| Net Interest Income |
|
-83.80
+1.32%
|
-84.91
-3.94%
|
-81.69
-208.91%
|
-26.45
|
| Interest Expense |
|
77.58
-3.34%
|
80.26
+5.25%
|
76.26
+239.59%
|
22.45
|
| Interest Income Non Operating |
|
0.00
-100.00%
|
2.23
+18.44%
|
1.88
|
—
|
| Interest Income |
|
0.00
-100.00%
|
2.23
+18.44%
|
1.88
|
—
|
| Other Income Expense |
|
-193.18
-400.69%
|
-38.58
-347.15%
|
15.61
-36.07%
|
24.42
|
| Other Non Operating Income Expenses |
|
-1.84
-6448.28%
|
0.03
-98.44%
|
1.86
+131.25%
|
-5.94
|
| Gain On Sale Of Security |
|
60.66
+14.29%
|
53.07
+25.01%
|
42.45
+344.29%
|
9.55
|
| Tax Provision |
|
5.03
+35.58%
|
3.71
+45.09%
|
2.56
+84.74%
|
1.38
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-40.18
-395.55%
|
-8.11
-380.71%
|
2.89
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Net Income From Continuing Operation Net Minority Interest |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Net Income From Continuing And Discontinued Operation |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Net Income Continuous Operations |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Normalized Income |
|
-1,125.62
-27.44%
|
-883.27
-16.15%
|
-760.43
-48.55%
|
-511.89
|
| Net Income Common Stockholders |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Diluted EPS |
|
-6.42
-15.26%
|
-5.57
-4.31%
|
-5.34
-36.57%
|
-3.91
|
| Basic EPS |
|
-6.42
-15.26%
|
-5.57
-4.31%
|
-5.34
-36.57%
|
-3.91
|
| Basic Average Shares |
|
199.01
+21.32%
|
164.04
+16.81%
|
140.43
+14.14%
|
123.03
|
| Diluted Average Shares |
|
199.01
+21.32%
|
164.04
+16.81%
|
140.43
+14.14%
|
123.03
|
| Diluted NI Availto Com Stockholders |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Amortization |
|
6.00
+18.78%
|
5.05
+0.00%
|
5.05
-0.02%
|
5.05
|
| Amortization Of Intangibles Income Statement |
|
6.00
+18.78%
|
5.05
+0.00%
|
5.05
-0.02%
|
5.05
|
| Depreciation Amortization Depletion Income Statement |
|
6.00
+18.78%
|
5.05
+0.00%
|
5.05
-0.02%
|
5.05
|
| Depreciation And Amortization In Income Statement |
|
6.00
+18.78%
|
5.05
+0.00%
|
5.05
-0.02%
|
5.05
|
| Total Other Finance Cost |
|
6.22
-9.70%
|
6.88
-5.96%
|
7.32
+83.41%
|
3.99
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
2,264.56
+11.82%
|
2,025.23
+52.29%
|
1,329.84
-19.72%
|
1,656.43
|
| Current Assets |
|
1,794.21
+10.64%
|
1,621.66
+74.55%
|
929.06
-27.04%
|
1,273.38
|
| Cash And Cash Equivalents |
|
510.44
-8.03%
|
555.03
+15.06%
|
482.37
-55.09%
|
1,074.04
|
| Other Short Term Investments |
|
919.60
+4.64%
|
878.80
+194.83%
|
298.07
+301.48%
|
74.24
|
| Receivables |
|
140.86
+170.82%
|
52.01
+26.28%
|
41.19
+38.62%
|
29.71
|
| Accounts Receivable |
|
140.86
+170.82%
|
52.01
+26.28%
|
41.19
+38.62%
|
29.71
|
| Inventory |
|
132.07
+33.97%
|
98.58
+18.41%
|
83.25
+19.06%
|
69.92
|
| Raw Materials |
|
30.62
+55.59%
|
19.68
-19.87%
|
24.56
-9.85%
|
27.25
|
| Work In Process |
|
41.35
+3.54%
|
39.93
+19.27%
|
33.48
+49.07%
|
22.46
|
| Finished Goods |
|
60.10
+54.24%
|
38.96
+54.58%
|
25.21
+24.68%
|
20.22
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
91.24
+144.96%
|
37.24
+54.04%
|
24.18
-5.06%
|
25.47
|
| Total Non Current Assets |
|
470.35
+16.55%
|
403.57
+0.70%
|
400.77
+4.63%
|
383.05
|
| Net PPE |
|
139.21
+20.44%
|
115.58
+10.73%
|
104.39
+2.26%
|
102.08
|
| Gross PPE |
|
199.97
+20.54%
|
165.89
+11.32%
|
149.01
+5.29%
|
141.53
|
| Accumulated Depreciation |
|
-60.76
-20.77%
|
-50.31
-12.72%
|
-44.63
-13.14%
|
-39.45
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
1.96
|
0.00
|
—
|
—
|
| Buildings And Improvements |
|
10.44
|
0.00
|
—
|
—
|
| Machinery Furniture Equipment |
|
15.02
+14.83%
|
13.08
+4.52%
|
12.52
+6.59%
|
11.74
|
| Construction In Progress |
|
42.41
-17.05%
|
51.13
+44.23%
|
35.45
+20.05%
|
29.53
|
| Other Properties |
|
76.73
+20.61%
|
63.62
+0.99%
|
63.00
-0.31%
|
63.20
|
| Leases |
|
53.40
+40.31%
|
38.06
+0.02%
|
38.05
+2.68%
|
37.06
|
| Goodwill And Other Intangible Assets |
|
233.76
+20.02%
|
194.76
-2.53%
|
199.81
-2.47%
|
204.87
|
| Goodwill |
|
136.11
+0.00%
|
136.11
+0.00%
|
136.11
+0.00%
|
136.11
|
| Other Intangible Assets |
|
97.65
+66.49%
|
58.65
-7.93%
|
63.70
-7.35%
|
68.76
|
| Investments And Advances |
|
—
|
—
|
—
|
0.00
|
| Other Non Current Assets |
|
97.38
+4.45%
|
93.23
-3.47%
|
96.57
+26.90%
|
76.10
|
| Total Liabilities Net Minority Interest |
|
1,525.58
-12.32%
|
1,739.85
+4.70%
|
1,661.76
+5.95%
|
1,568.48
|
| Current Liabilities |
|
468.87
+57.59%
|
297.53
+31.87%
|
225.63
+18.60%
|
190.24
|
| Payables And Accrued Expenses |
|
344.55
+68.16%
|
204.90
+28.58%
|
159.35
+14.33%
|
139.38
|
| Payables |
|
103.46
+23.85%
|
83.53
+12.26%
|
74.41
+29.82%
|
57.32
|
| Accounts Payable |
|
79.91
+9.41%
|
73.03
+11.68%
|
65.39
+29.59%
|
50.46
|
| Other Payable |
|
23.55
+124.26%
|
10.50
+16.41%
|
9.02
+31.52%
|
6.86
|
| Current Accrued Expenses |
|
241.09
+98.65%
|
121.36
+42.88%
|
84.94
+3.51%
|
82.06
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
111.51
+38.85%
|
80.31
+64.13%
|
48.93
+52.72%
|
32.04
|
| Current Debt And Capital Lease Obligation |
|
12.81
+4.02%
|
12.32
+15.76%
|
10.64
+30.96%
|
8.13
|
| Current Capital Lease Obligation |
|
12.81
+4.02%
|
12.32
+15.76%
|
10.64
+30.96%
|
8.13
|
| Current Deferred Liabilities |
|
—
|
24.70
+268.66%
|
6.70
-37.38%
|
10.70
|
| Total Non Current Liabilities Net Minority Interest |
|
1,056.71
-26.74%
|
1,442.32
+0.43%
|
1,436.13
+4.20%
|
1,378.24
|
| Long Term Debt And Capital Lease Obligation |
|
573.86
-49.51%
|
1,136.56
-4.76%
|
1,193.35
+2.02%
|
1,169.74
|
| Long Term Debt |
|
540.96
-50.97%
|
1,103.38
-4.49%
|
1,155.31
+2.67%
|
1,125.25
|
| Long Term Capital Lease Obligation |
|
32.89
-0.85%
|
33.18
-12.78%
|
38.04
-14.50%
|
44.49
|
| Other Non Current Liabilities |
|
482.85
+57.92%
|
305.77
+25.94%
|
242.78
+16.44%
|
208.50
|
| Stockholders Equity |
|
738.98
+158.95%
|
285.38
+185.98%
|
-331.92
-477.40%
|
87.95
|
| Common Stock Equity |
|
738.98
+158.95%
|
285.38
+185.98%
|
-331.92
-477.40%
|
87.95
|
| Capital Stock |
|
2.14
+19.45%
|
1.79
+21.22%
|
1.48
+9.06%
|
1.36
|
| Common Stock |
|
2.14
+19.45%
|
1.79
+21.22%
|
1.48
+9.06%
|
1.36
|
| Share Issued |
|
214.26
+19.44%
|
179.38
+21.22%
|
147.98
+9.09%
|
135.65
|
| Ordinary Shares Number |
|
214.26
+19.44%
|
179.38
+21.22%
|
147.98
+9.09%
|
135.65
|
| Additional Paid In Capital |
|
6,372.06
+37.16%
|
4,645.79
+49.22%
|
3,113.49
+11.90%
|
2,782.42
|
| Retained Earnings |
|
-5,636.69
-29.28%
|
-4,359.92
-26.52%
|
-3,446.14
-27.80%
|
-2,696.58
|
| Gains Losses Not Affecting Retained Earnings |
|
1.46
+163.83%
|
-2.29
-207.25%
|
-0.74
-198.54%
|
0.76
|
| Other Equity Adjustments |
|
1.46
+163.83%
|
-2.29
-207.25%
|
-0.74
-198.54%
|
0.76
|
| Total Equity Gross Minority Interest |
|
738.98
+158.95%
|
285.38
+185.98%
|
-331.92
-477.40%
|
87.95
|
| Total Capitalization |
|
1,279.94
-7.84%
|
1,388.76
+68.66%
|
823.39
-32.13%
|
1,213.20
|
| Working Capital |
|
1,325.33
+0.09%
|
1,324.13
+88.24%
|
703.43
-35.06%
|
1,083.14
|
| Invested Capital |
|
1,279.94
-7.84%
|
1,388.76
+68.66%
|
823.39
-32.13%
|
1,213.20
|
| Net Debt |
|
30.52
-94.43%
|
548.35
-18.51%
|
672.94
+1213.97%
|
51.21
|
| Capital Lease Obligations |
|
45.71
+0.47%
|
45.49
-6.54%
|
48.68
-7.48%
|
52.62
|
| Net Tangible Assets |
|
505.21
+457.53%
|
90.62
+117.04%
|
-531.74
-354.81%
|
-116.92
|
| Tangible Book Value |
|
505.21
+457.53%
|
90.62
+117.04%
|
-531.74
-354.81%
|
-116.92
|
| Interest Payable |
|
0.00
-100.00%
|
0.36
-83.49%
|
2.17
-65.69%
|
6.34
|
| Investmentin Financial Assets |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-935.01
-36.72%
|
-683.88
-27.53%
|
-536.25
-33.91%
|
-400.44
|
| Cash Flow From Continuing Operating Activities |
|
-935.01
-36.72%
|
-683.88
-27.53%
|
-536.25
-33.91%
|
-400.44
|
| Net Income From Continuing Operations |
|
-1,276.78
-39.73%
|
-913.77
-21.91%
|
-749.57
-55.66%
|
-481.53
|
| Depreciation Amortization Depletion |
|
16.45
+49.37%
|
11.01
+4.10%
|
10.58
+2.40%
|
10.33
|
| Depreciation |
|
10.45
+75.29%
|
5.96
+7.85%
|
5.53
+4.72%
|
5.28
|
| Amortization Cash Flow |
|
6.00
+18.78%
|
5.05
+0.00%
|
5.05
-0.02%
|
5.05
|
| Depreciation And Amortization |
|
16.45
+49.37%
|
11.01
+4.10%
|
10.58
+2.40%
|
10.33
|
| Amortization Of Intangibles |
|
6.00
+18.78%
|
5.05
+0.00%
|
5.05
-0.02%
|
5.05
|
| Other Non Cash Items |
|
291.25
+102.05%
|
144.14
-18.51%
|
176.88
+3454.03%
|
4.98
|
| Stock Based Compensation |
|
152.71
+57.70%
|
96.83
+29.50%
|
74.78
+29.63%
|
57.69
|
| Operating Gains Losses |
|
—
|
0.24
+173.75%
|
-0.32
-120.97%
|
1.53
|
| Gain Loss On Investment Securities |
|
—
|
0.24
+173.75%
|
-0.32
-120.97%
|
1.53
|
| Change In Working Capital |
|
-80.30
-2427.51%
|
-3.18
+91.90%
|
-39.22
-696.47%
|
6.58
|
| Change In Receivables |
|
-88.31
-582.86%
|
-12.93
-8.10%
|
-11.96
-86.25%
|
-6.42
|
| Changes In Account Receivables |
|
-88.31
-582.86%
|
-12.93
-8.10%
|
-11.96
-86.25%
|
-6.42
|
| Change In Inventory |
|
-31.52
-84.93%
|
-17.04
-25.20%
|
-13.61
-694.22%
|
-1.71
|
| Change In Prepaid Assets |
|
-53.43
-276.75%
|
-14.18
-726.14%
|
2.27
-10.40%
|
2.53
|
| Change In Payables And Accrued Expense |
|
100.07
+124.42%
|
44.59
+194.24%
|
15.15
-69.70%
|
50.01
|
| Change In Payable |
|
—
|
—
|
—
|
—
|
| Change In Account Payable |
|
—
|
—
|
—
|
—
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
-2.12
-125.47%
|
8.34
+141.52%
|
-20.07
+20.48%
|
-25.24
|
| Change In Other Current Liabilities |
|
-4.99
+58.21%
|
-11.95
-8.72%
|
-10.99
+12.68%
|
-12.58
|
| Investing Cash Flow |
|
-64.58
+88.93%
|
-583.17
-160.81%
|
-223.60
-546.55%
|
-34.58
|
| Cash Flow From Continuing Investing Activities |
|
-64.58
+88.93%
|
-583.17
-160.81%
|
-223.60
-546.55%
|
-34.58
|
| Net PPE Purchase And Sale |
|
-32.56
-48.52%
|
-21.92
-64.98%
|
-13.29
-34.52%
|
-9.88
|
| Purchase Of PPE |
|
-32.56
-48.52%
|
-21.92
-64.98%
|
-13.29
-34.52%
|
-9.88
|
| Capital Expenditure |
|
-32.56
-48.52%
|
-21.92
-64.98%
|
-13.29
-34.52%
|
-9.88
|
| Net Investment Purchase And Sale |
|
-2.01
+99.64%
|
-561.25
-162.59%
|
-213.73
-765.11%
|
-24.71
|
| Purchase Of Investment |
|
-2,092.01
-32.64%
|
-1,577.25
-167.91%
|
-588.73
-490.47%
|
-99.71
|
| Sale Of Investment |
|
2,090.00
+105.71%
|
1,016.00
+170.93%
|
375.00
+400.00%
|
75.00
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Gain Loss On Sale Of Business |
|
—
|
—
|
76.48
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Net Other Investing Changes |
|
-30.00
|
—
|
3.42
|
—
|
| Financing Cash Flow |
|
954.07
-28.85%
|
1,341.02
+696.15%
|
168.44
-78.77%
|
793.27
|
| Cash Flow From Continuing Financing Activities |
|
954.07
-28.85%
|
1,341.02
+696.15%
|
168.44
-78.77%
|
793.27
|
| Net Issuance Payments Of Debt |
|
-4.93
-103.34%
|
147.39
+12210.93%
|
-1.22
-100.35%
|
349.40
|
| Issuance Of Debt |
|
0.00
-100.00%
|
150.00
|
0.00
-100.00%
|
350.00
|
| Repayment Of Debt |
|
-4.93
-88.74%
|
-2.61
-114.46%
|
-1.22
-102.50%
|
-0.60
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
150.00
|
0.00
-100.00%
|
350.00
|
| Long Term Debt Payments |
|
-4.93
-88.74%
|
-2.61
-114.46%
|
-1.22
-102.50%
|
-0.60
|
| Net Long Term Debt Issuance |
|
-4.93
-103.34%
|
147.39
+12210.93%
|
-1.22
-100.35%
|
349.40
|
| Net Common Stock Issuance |
|
823.28
-24.06%
|
1,084.12
+611.02%
|
152.47
-47.81%
|
292.15
|
| Proceeds From Stock Option Exercised |
|
135.72
+19.85%
|
113.24
+515.48%
|
18.40
-5.67%
|
19.50
|
| Net Other Financing Charges |
|
—
|
-3.74
-206.81%
|
-1.22
-100.92%
|
132.22
|
| Changes In Cash |
|
-45.52
-161.54%
|
73.96
+112.51%
|
-591.41
-265.08%
|
358.25
|
| Effect Of Exchange Rate Changes |
|
0.93
+171.23%
|
-1.31
-422.80%
|
-0.25
+74.90%
|
-1.00
|
| Beginning Cash Position |
|
555.03
+15.06%
|
482.37
-55.09%
|
1,074.04
+49.84%
|
716.78
|
| End Cash Position |
|
510.44
-8.03%
|
555.03
+15.06%
|
482.37
-55.09%
|
1,074.04
|
| Free Cash Flow |
|
-967.58
-37.09%
|
-705.80
-28.44%
|
-549.53
-33.93%
|
-410.32
|
| Interest Paid Supplemental Data |
|
55.35
+36.45%
|
40.57
+13.36%
|
35.79
+252.34%
|
10.16
|
| Income Tax Paid Supplemental Data |
|
4.14
+65.71%
|
2.50
+27.83%
|
1.96
+13.86%
|
1.72
|
| Amortization Of Securities |
|
-38.35
-100.15%
|
-19.16
-104.20%
|
-9.38
|
0.00
|
| Common Stock Issuance |
|
823.28
-24.06%
|
1,084.12
+611.02%
|
152.47
-47.81%
|
292.15
|
| Issuance Of Capital Stock |
|
823.28
-24.06%
|
1,084.12
+611.02%
|
152.47
-47.81%
|
292.15
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-17 View
- 42026-04-08 View
- 8-K2026-04-07 View
- 42026-04-03 View
- 42026-03-31 View
- 8-K2026-03-23 View
- 42026-03-20 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-02-27 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-23 View
- 10-K2026-02-19 View
- 8-K2026-02-19 View
- 42026-02-11 View
- 42026-02-11 View
- 42026-02-06 View
- 42026-02-04 View
- 42026-02-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|